Nebulised lIposomal aMphotericin B in chronic pUlmonary aSpergillosis: a deposition study
This study is investigating a new way to give a medicine called AmBisome to people with a long-term lung infection caused by a fungus, known as chronic pulmonary aspergillosis. Instead of an injection, the medicine is breathed in as a fine mist (nebulised). The main goal is to see how much of this inhaled medicine actually gets into the lungs and how it moves around the body, to find the most effective and safest dose. Researchers will use special scans to track the medicine and will also carefully monitor participants for any side effects. This research aims to improve treatment options for chronic pulmonary aspergillosis.
At a glance
What is this study about?
This study is about a long-term lung infection called chronic pulmonary aspergillosis. This infection is caused by a type of fungus. When people have this condition, the fungus can cause ongoing inflammation and damage in their lungs, leading to symptoms like coughing and breathlessness.
The researchers are looking at a medicine called AmBisome. Currently, this medicine is often given through a drip, but this study is exploring whether giving it as a mist that participants breathe in (called nebulised AmBisome) could be a better way to deliver it directly to the lungs. Using a mist means the medicine goes straight to where the infection is.
The main purpose of the study is to see exactly how much of this inhaled AmBisome medicine reaches the lungs using special scans. They will also look at how the medicine is absorbed and moves through the body, and compare this to how much is in the lungs. By doing this, they hope to find the right dose of inhaled AmBisome that works best for treating the infection while keeping side effects to a minimum.
Key takeaways
- This study is looking at an inhaled treatment for a fungal lung infection.
- It aims to find the best way to deliver AmBisome medicine directly to the lungs as a mist.
- Special scans will track how much medicine reaches the lungs.
- Researchers will also monitor for any side effects.
- The study helps find the right dose for future use in patients.
- It could lead to better treatments for chronic pulmonary aspergillosis.
Who may be eligible?
To be considered for this study, you need to be an adult, meaning you are 18 years old or older. There is no upper age limit, so older adults can also take part.
Both men and women are welcome to participate in this research. The study is open to people of all genders.
Specific medical details about your health and your chronic pulmonary aspergillosis would also be needed to ensure the study is safe and appropriate for you. This would be discussed in detail by the study team.
- Are you 18 years old or older?
- Do you have chronic pulmonary aspergillosis?
- Are you able to breathe in medicine through a nebuliser?
- Are you comfortable having special scans and blood tests?
- Have you discussed your participation with your doctor?
This is a guide only — the research team will confirm whether you can take part.
What does participation involve?
If you join this study, you will be given the AmBisome medicine as a mist to breathe in. You will have special scans, called SPECT/CT scans, to see how much of the medicine reaches your lungs. You will also have blood tests to check how the medicine is moving through your body. The team will ask you questions about how you feel and any side effects you might experience, and you might fill out questionnaires. The study will also include checks on your lung function. The total duration of your participation, including visits and follow-ups, will be clearly explained by the study team.
Potential risks and benefits
Locations (1)
- —Netherlands
Common questions
What is chronic pulmonary aspergillosis?
It's a long-lasting lung infection caused by a common type of fungus called Aspergillus.
What does 'nebulised' mean?
It means the medicine is turned into a fine mist that you breathe directly into your lungs.
What is AmBisome?
It's a medicine used to treat serious fungal infections, including those in the lungs.
Will this study cure my condition?
This is an early-stage study primarily focused on understanding how the medicine works, not a direct treatment for your condition at this stage. It helps develop better treatments for the future.
What is a SPECT/CT scan?
It's a special type of scan that helps doctors see where the medicine goes inside your body, particularly in your lungs.
How to find out more
Always speak to your GP or specialist before deciding to take part in a study.
Discussion
Community discussion
Powered by our forum at community.patient.info. Please be respectful — this is not medical advice.